Immuno-Oncology Model Application in the Preclinical Treatment Setting

Transcription

1 Immuno-Oncology Model Application in the Preclinical Treatment Setting Maryland Franklin, Ph.D. Senior Director, Scientific Development July 22, 2015 Tumor Models Conference Boston, MA 2015

2 Molecular Imaging: Your Partner in Preclinical Oncology CONFIDENTIAL In Vitro Services In Vivo Services In Vivo Imaging Services Flow cytometry qpcr Western blots High-content image analysis Proliferation assays Plate-based assays Cytometric bead arrays 350+ cell line models Syngeneic and xenografts 400+ PDX models for in vivo imaging SC, orthotopic, metastatic & disseminated models MRI (7T, 11.7T) PET SPECT CT BLI FLI FMT Ultrasound DEXA 2D-Xray All the tools to provide support and remove variability throughout the preclinical process

3 CONFIDENTIAL Cancer Immunotherapy Paradigm Tumor cells are caught between self escape and host elimination mechanisms Successful tumors evade host immunity and propagate Immunotherapies bolster host immunity to actively eliminate the tumor

4 CONFIDENTIAL Available Syngeneic Models Solid Tumor Lines Histotype Tumor Line(s) Breast 4T1, 4T1-luc, MMV-PyMT Colon C26, CT26.WT, C51 Melanoma B16, B16.F10, B16.F10-luc Lung Lewis Lung, LL/2-luc Glioma GL261, GL261-luc Pancreas Pan02, Pan03 Sarcoma RIF-1 Neuroblastoma Neuro-2a Histotype Leukemia Lymphoma Myeloma Mastocytoma Disseminated Tumor Lines Tumor Line(s) L1210, M-NFS-60, J774.A1, RAW 264.7, P388 A20, E.G7-OVA (EL4 derivative) 5TGM-1, 5TGM-1-luc P815 We have a large number of syngeneic lines Growth curves available on many lines Some lines have SoC treatment data

5 CONFIDENTIAL Treatment Response Data Response varies depending on the model B16.F10 RIF-1 days of dosing Dosing: days 3, 6, 10, 13, 16 4T1-luc days of dosing B16.F10 is not responsive to anti-ctla- 4 treatment 4T1-luc shows little response to anti- CTLA-4 treatment RIF-1 shows ~40% response to anti- CTLA-4 treatment but is non-responsive to anti-pd-l1 treatment

6 CT26.WT Syngeneic Model Treatment with anti-ctla-4 or anti-pd-l1 antibodies Vehicle control Isotype for anti-pd-l1 Ab Isotype for anti-ctla-4 ab Anti-PD-L1 Antibody Anti-CTLA-4 Antibody CT-26.WT Response to anti-pd-l1 treatment 4/10 responders 1 tumor free mouse on d18 Response to anti-ctla-4 treatment 10/10 responders 7 tumor free mice on d18 3 mice from each group were sampled on d18 Tumors and spleens CD4/CD8 T cells Tregs MDSCs Surface markers Tumor Burden (mm 3 ) Anti-CTLA4 antibody,10mg/kg Days 3, 6, 10, 13 & Days Post Tumor Implant CONFIDENTIAL

7 Treatment Related Flow Cytometry Data CT26 tumors following treatment with anti-pd-l1 antibody 19.7% 3.1% 5.32% Isotype Control Anti-PD-L1 Treatment RL2-A: CD8aAPC-AlexaFluor 750 RL2-A: CD8aAPC-AlexaFluor % BL1-A:CD4 FITC RL1-A: GR-1 APC RL1-A: GR-1 APC BL2-A:CD11b PE 0.74% FoxP3 APC FoxP3 APC FoxP3 APC CD25 PE 1.47% BL1-A:CD4 FITC Increased CD8+ T-cells BL2-A:CD11b PE Decreased MDSC cells CONFIDENTIAL CD25 PE Decreased Treg cells

8 Treatment Related Flow Cytometry Data CT26 tumors following treatment with anti-ctla-4 antibody 3.1% 32.67% 2.83% 5.19% Isotype Control Anti-CTLA4 Treatment 41.85% RL1-A: GR-1 APC RL1-A: GR-1 APC 3.52% RL2-A: FoxP3 APC RL2-A: FoxP3 APC BL1-A: CD25 PE 3.66% BL1-A: CD25 PE Increased CD8+ T-cells Equivalent MDSC cells Decreased Treg cells CONFIDENTIAL

9 CONFIDENTIAL Treatment Related Flow Cytometry Data Tumor PD-L1 expression following treatment with anti-ctla-4 antibody Isotype Control Anti-CTLA-4 Treatment Live cell gate Lymphocyte gate

10 Examples of Tumor Profiling MDSC 4T1-luc Tumor Model DC B16.F10 Tumor Model CD8+ T cells (58%) MDSC (1.2%) TAM T cells Tregs (8.5%) CONFIDENTIAL

11 CONFIDENTIAL Radiation Therapy and Immunotherapy Ionizing Radiation: Modify TME Induce cytokines and chemokines Potential to synergize with immune modulatory agents Remains a highly utilized clinical treatment modality MII has radiation capabilities MII has GL261-luc model Baseline data on antitumor effects and overall survival following radiation treatment Zeng et al., Int J Radiat Oncol Biol Phys, 2013 Control Radiation

12 In Vivo Cell Tracking in vivo Cell Tracking with 19F MRI Imaging stem cell engraftment in the mouse whole body following IV administration Cell concentration Standard Project Design 19 F labeling of cells in vitro (using Cell Sense) ex vivo pilot with NMR in vivo whole body MRI cell engraftment and biodistribution time course 19 F MRI color signal (cell concentration) on greyscale anatomical MRI 11.7T Bruker MRI system for maximum sensitivity 19F-MRI with 11.7T system (19F cell signal as color overlay on greyscale anatomical MRI) CONFIDENTIAL

13 CONFIDENTIAL Conclusions At Molecular Imaging we have a large number of syngeneic tumor lines We have characterized the immune profile of several of these lines with more work ongoing We have investigated the treatment related effects of immune checkpoint inhibitors on solid tumor models Direct anti-tumor effects Immune modulatory effects We have some unique models to allow investigation into multiple myeloma and glioblastoma We are evaluating T cell tracking through 19 F-MRI

14 Thank You CONFIDENTIAL